p53 signaling in cancer progression and therapy

Сигналинг p53 в прогрессии и терапии рака
Anwarul Hasan, Antonio Giordano, Nahla M. Afifi, Andrea Morrione, Hany E. S. Marei, Asmaa A. Al Thani, Thomas Caceci, Giacomo Pozzoli, Carlo Cenciarelli
2021-12-01

TP53 mutationscancer therapymutant p53p53 signalingtumor suppressor
The p53 protein is a transcription factor known as the "guardian of the genome" because of its critical function in preserving genomic integrity. The TP53 gene is mutated in approximately half of all human malignancies, including those of the breast, colon, lung, liver, prostate, bladder, and skin. When DNA damage occurs, the TP53 gene on human chromosome 17 stops the cell cycle. If p53 protein is mutated, the cell cycle is unrestricted and the damaged DNA is replicated, resulting in uncontrolled cell proliferation and cancer tumours. Tumor-associated p53 mutations are usually associated with phenotypes distinct from those caused by the loss of the tumor-suppressing function exerted by wild-type p53protein. Many of these mutant p53 proteins have oncogenic characteristics, and therefore modulate the ability of cancer cells to proliferate, escape apoptosis, invade and metastasize. Because p53 deficiency is so common in human cancer, this protein is an excellent option for cancer treatment. In this review, we will discuss some of the molecular pathways by which mutant p53 proteins might perform their oncogenic activities, as well as prospective treatment methods based on restoring tumor suppressive p53 functions.
1
Because p53 deficiency is widespread in cancer, restoring tumor-suppressive p53 functions represents a promising therapeutic strategy.
2
Many tumor-associated p53 mutants exert oncogenic gain-of-function effects beyond loss of tumor suppression, promoting proliferation, apoptosis evasion, invasion, and metastasis.
3
TP53 is mutated in approximately half of all human malignancies, spanning cancers of the breast, colon, lung, liver, prostate, bladder, and skin.
4
The review examines molecular pathways underlying mutant p53 oncogenic activity and prospective treatments designed to restore p53-mediated tumor suppression.
5
Wild-type p53 responds to DNA damage by arresting the cell cycle, whereas p53 mutations permit replication of damaged DNA and uncontrolled proliferation.

p53 signaling in human cancer and tumor-associated mutant p53 proteins

the molecular mechanisms by which mutant p53 promotes cancer-cell proliferation, apoptosis evasion, invasion, and metastasis, and therapeutic restoration of tumor-suppressive p53 functions

Publication Details
Publication Date
2021-12-01
Journal
Publisher
ISSN
Cited by
650
Access Type
Author Information
Authors
Anwarul Hasan
Antonio Giordano
Nahla M. Afifi
Andrea Morrione
Hany E. S. Marei
Asmaa A. Al Thani
Thomas Caceci
Giacomo Pozzoli
Carlo Cenciarelli
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%